Clinical Trials Logo
  1. Home
  2. Systemic Scleroderma
  3. NCT03262922

Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment — PRESSY  

Systemic Scleroderma Clinical Trial

Official title:
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment

Clinical Trial Summary

The aim of the study is to compare the exposure to environmental and professional toxics by patients with systemic scleroderma and by patients not achieved by this pathology.

Clinical Trial Description

This study is based on a questionnaire. The data will be collected according a retrospective and prospective design : - at diagnostic of the disease - at the inclusion in the systemic scleroderma cohort - during the annual visit (in 2017-2018-2019-2020) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03262922
Study type Observational
Source Rennes University Hospital
Contact
Status Completed
Phase
Start date July 29, 2016
Completion date February 18, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03629002 - BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
Terminated NCT00377455 - Placebo Controlled Trial of Bosentan in Scleroderma Patients Phase 2
Completed NCT00318188 - Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis N/A
Completed NCT00278525 - Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Phase 2
Completed NCT03575156 - Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis N/A
Active, not recruiting NCT01413100 - Scleroderma Treatment With Autologous Transplant (STAT) Study Phase 2
Completed NCT00622895 - Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03816189 - Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
Completed NCT01295736 - Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Phase 3
Completed NCT02213705 - Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Phase 1/Phase 2
Recruiting NCT03508375 - Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis N/A
Active, not recruiting NCT01309997 - Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Phase 2
Completed NCT00697736 - Cardiac Repercussion of Systemic Sclerodermias N/A
Completed NCT02349009 - Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial Phase 1/Phase 2
Completed NCT00318175 - Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis Phase 2
Recruiting NCT03816345 - Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Phase 1
Recruiting NCT04380831 - TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis Early Phase 1
Terminated NCT00628797 - Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis Phase 1/Phase 2
Recruiting NCT05672992 - Longitudinal Spatial Frequency Domain Imaging Study N/A
Recruiting NCT05726630 - Clinical Study of Divozilimab in Patients With Systemic Scleroderma Phase 3